Identification of apolipoprotein D as a novel inhibitor of osteopontin-induced neoplastic transformation

International Journal of Oncology

Volumn 29, Issue 6, 2006, Pages 1591-1599

  Jin, Dachuan ^a   El Tanani, Mohamed ^a   Campbell, Frederick Charles ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Apolipoprotein D; Bacterial two hybrid; cDNA library; Co repressor; Neoplasms; Osteopontin

Indexed keywords

APOLIPOPROTEIN D; COMPLEMENTARY DNA; OSTEOPONTIN;

ANIMAL; ARTICLE; BREAST; BREAST TUMOR; CELL ADHESION; CELL GROWTH; CELL TRANSFORMATION; CYTOLOGY; DRUG ANTAGONISM; EPITHELIUM CELL; FEMALE; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOPRECIPITATION; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; RAT; UDDER;

ANIMALS; APOLIPOPROTEINS D; BASE SEQUENCE; BREAST; BREAST NEOPLASMS; CELL ADHESION; CELL GROWTH PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; DNA, COMPLEMENTARY; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOPRECIPITATION; MAMMARY GLANDS, ANIMAL; MOLECULAR SEQUENCE DATA; OSTEOPONTIN; RATS; TRANSFECTION;

EID: 39049180049     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.6.1591     Document Type: Article

References (82)

1. Butler WT: The nature and significance of osteopontin. Connect Tissue 23: 123-136, 1989.
2. Sorensen ES, Hojrup P and Peterson TE: Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites. Protein Sci 4: 2040-2049, 1995.
3. Senger DR, Wirth DF and Hynes RO: Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16: 885-893, 1979.
4. Brown LF, Berse B, Water L Van De and Papadopoulos-Sergiou A: Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell 3: 1169-1180, 1992. (Pubitemid 23088966)
5. Senger DR, Perruzzi CA and Papadopoulos A: Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 9: 1291-1300, 1989.
6. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Eognazzi K, Perruzzi CA, Dvorak AM and Senger DR: Osteopontin expression and distribution in human carcinomas. Am J Pathol 145: 610-623, 1994. (Pubitemid 24285968)
7. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS and Chambers AF: Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer (Pred Oncol): 79: 502-508, 1998. (Pubitemid 28445273)
8. Oates AJ, Barraclough R and Rudland PS: The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 17: 1-15, 1997.
9. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF and Harris JF: Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3: 605-611, 1997.
10. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T and Tahara E: Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 79: 127-132, 1998. (Pubitemid 28201682)
11. Shijubo N, Uede T, Kon S, Maeda M, Segawa T, Imada A, Hirasawa M and Abe S: Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 160: 1269-1273, 1999.
12. Gotoh M, Sakamoto M, Kanetaka K, Chuuma M and Hirohashi S: Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 52: 19-24, 2002.
13. Senger DR, Wirth DF and Hynes RO: Transformation-specific secreted phosphoproteins. Nature 286: 619-621, 1980.
14. Senger DR, Asch BB, Smith BD, Perruzzi CA and Dvorak HF: A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature 302: 714-715, 1983.
15. Carig AM, Nemir M, Mukherjee BB, Chambers AF and Denhardt DT: Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin: enhanced expression in H-ras-transfromed 3T3 cells. Biochem Biophys Res Commun 157: 166-173, 1988. (Pubitemid 19004841)
16. Tuck AB, Wilson, SM, Khokha R and Chambers AF: Different patterns of gene expression in ras-resistant and ras-sensitive cells. J Natl Cancer Inst 83: 485-491, 1991.
17. Chambers AF, Behrend EI, Wilson SM and Denhardt DT: Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. Anticancer Res 12: 43-47, 1992.
18. Craig AM, Bowden GT, Chambers AF, Spearman MA, Greenberg AH, Wright JA, McLeod M and Denhardt DT: Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. Int J Cancer 46: 133-137, 1990. (Pubitemid 20225799)
19. Craig AM, Nemir M, Mukherjee BB, Chambers AF and Denhardt DT: Osteopontin, a transformation associated cell adhesion phosphoprotein, is induced by 12-O-tetradecanoylphorbol 13-acetate in mouse epidermis. J Biol Chem 264: 9682-9689, 1989.
20. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R and West CR: Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62: 3417-3427, 2002.
21. Fedarko NS, Jain A, Karadag A, Eman MRV and Fisher LW: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7: 4060-4066, 2001. (Pubitemid 34044628)
22. Behrend EJ, Craig AM, Wilson SM, Denhardt DT and Chambers AF: Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 54: 832-837, 1994.
23. Gardner HA, Berse B and Senger DR: Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene 9: 2321-2326, 1994. (Pubitemid 24228683)
24. Su L, Mukherjee AB and Mukherjee BB: Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells. Oncogene 10: 2163-2169, 1995.
25. Feng B, Rollo EE and Denhardt DT: Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: evidence from cell lines down-regulated for OPN expression by targeted ribozyme. Oncogene 13: 453-462, 1995.
26. Hirama M, Takahashi F, Takahashi K, Akutagawa S, Shimizu K, Soma S, Shimanuki Y and Nishio KYF: Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett 198: 107-117, 2003.
27. Furger KA, Menon RK, Tuck AB and Bramwell VHC, Chambers AF: The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1: 621-632, 2001. (Pubitemid 33772040)
28. Adwan H, Bauerle T, Najajreh Y, Elazer V, Golomb G and Berger MR: Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int J Oncol 24: 1235-1244, 2004.
29. Tuck AB, Hota C, Wilson SM and Chambers AF: Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathway. Oncogene 22: 1198-1205, 2003. (Pubitemid 36363383)
30. Tuck AB and Chambers AF: The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 6: 419-429, 2001. (Pubitemid 39600499)
31. El-Tanani M, Barraclough R, Wilkinson MC and Rudland PS: Metastasis-inducing DNA regulates the expression of the osteopontin gene by binding the transcription factor Tcf-4. Cancer Res 61: 5619-5629, 2001.
32. Oates AJ, Barraclough R and Rudland PS: The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumor model. Oncogene 13: 97-104, 1996. (Pubitemid 26248549)
33. Bailey J, Tyson-Capper AJ, Gilmore K, Robson SC and Europe-Finner GN: Identification of human myometrial target genes of the cAMP pathway: the role of cAMP-response element binding (CREB) and modulator (CREMalpha and CREMtao2alpha) proteins. J Mol Endocrinol 34: 1-17, 2005.
34. Reckless J, Rubin EM, Verstuyft JB, Metcalfe JC and Grainger DJ: A common phenotype associated with atherogenesis in diverse mouse models of vascular lipid lesions. J Vasc Res 38: 256-265, 2001.
35. Cifone MA and Fidler IJ: Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc Natl Acad Sci USA 77: 1039-1043, 1980.
36. van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ, Broekhoven MG and Langenhuijsen MM: A tetrazolium-based colorimetric MTT assay to quantite human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods 174: 311-320, 1994.
37. Boyd DD, Levine AE, Brattain DE, McKnight MK and Brattain MG: Comparison of growth requirements of two human intratumoral colon carcinoma cell lines in monolayer and soft agarose. Cancer Res 48: 2469-2474, 1988.
38. Moye VE BR, West C and Rudland PS: Osteopontin expression correlates with adhesive and metastatic potential in metastasis-inducing DNA-transfected rat mammary cell lines. Br J Cancer 90: 1796-1802, 2004.
39. Eliasv JM: Cell proliferation indexes: a biomarker in solid tumors. Biotech Histochem 72: 78-85, 1997.
40. Kikuchi Y, Dinjens WN and Bosman FT: Proliferation and apoptosis in proliferative lesions of the colon and rectum. Virchows Arch 431: 111-117, 1997.
41. McConathy WJ and Alaupovic P: Isolation and partial characterization of apolipoprotein D: a new protein moiety of the human plasma lipoprotein system. FEBS Letter 37: 178-182, 1973.
42. Lea OA, Kvinnsland S and Thorsen T: Progesterone-binding cyst protein in human breast tumor cytosol. Cancer Res 47: 6189: 1987.
43. Lopez-Boado YS, Tolivia J and Lopez-Otin C: Apolipoprotein D gene induction by retinoic acid is concomitant with growth arrest and cell differentiation in human breast cancer cells. J Biol Chem 269: 26871-26878, 1994.
44. Lopez-Boado YS, Puente XS, Alvarez S, Tolivia J, Binderup L and Lopez-Otin C: Growth inhibition of human breast cancer cells by 1,25-dihydroxyvitamin D3 is accompanied by induction of apolipoprotein D expression. Cancer Res 57: 4091-4097, 1997.
45. Lopez-Boado YS, Klaus M, Dawson MI and Lopez-Otin C: Retinoic acid-induced expression of apolipoprotein D and concomitant growth arrest in human breast cancer cells are mediated through a retinoic acid receptor RARalpha-dependent signaling pathway. J Biol Chem 271: 32105-32111, 1996.
46. Diaz CS, Vizoso F, Lamelas ML, Rodriguez JC, Gonzalez LO, Baltasar A and Medrano J: Expression and clinical significance of apolipoprotein D in male breast cancer and gynaecomastia. Br J Surg 86: 1190-1197, 1999.
47. Simard J, de Launoit Y, Haagensen DE and Labrie F: Additive stimulatory action of glucocorticoids and androgens on basal and estrogen-repressed apolipoprotein-D messenger ribonucleic acid levels and secretion in human breast cancer cells. Endocrinology 130: 1115-1121, 1992.
48. Diez-Itza I, Vizoso F, M Merino A, Sanchez LM, Tolivia J, Fernandez J, Ruibal A and Lopez-Otin C: Expression and prognostic significance of apolipoprotein D in breast cancer. Am J Pathol 144: 310-320, 1994.
49. Sanchez LM, Vizoso F, Diez-Itza C and Lopez-Otin C: Identification of the major protein components in breast secretions from women with benign and malignant breast diseases. Cancer Res 52: 95-100, 1992.
50. Albers JJ, Cheung MC, Ewens SL and Tollefson JH: Characterization and immunoassay of apolipoprotein D. Atherosclerosis 39: 395-409, 1981.
51. Drayna D, Fielding C, McLean J, et al: Cloning and expression of human apolipoprotein D cDNA. J Biol Chem 261: 16535-16539, 1986.
52. Weech PK, Camato MC and Ewens SL: Apolipoprotein D and cross-reacting human plasma apolipoproteins identified using monoclonal antibodies. J Biol Chem 261: 7941-7951, 1986. (Pubitemid 17208727)
53. Drayna DT: Human apolipoprotein D gene: gene sequence, chromosome localization, and homology to the alpha 2uglobulin superfamily. DNA 6: 199-204, 1987.
54. Rassart E, Bedirian A, Carmo SD, Guinard O, Sirois J, Terrisse L and Milne R: Apolipoprotein D. Biochim Biophys Acta 1482: 185-198, 2000.
55. Boyles JK, Notterpek LM, Wardell MR and Rall SC: Identification, characterization, and tissue distribution of apolipoprotein D in the rat. J Lipid Res 31: 2243-2256, 1990.
56. Terisse L, Marcoux K, Carmo SD, Brissette L, Milne R and Rassart E: Structure-function relationships of human apolipoprotein D an immunochemical analysis. Life Sci 70: 629-638, 2001. (Pubitemid 34056560)
57. Cabral JHM, Atkins G, Sanchez LM, Lopez-Boado YS, Lopez-Otin C and Sawyer L: Arachidonic acid binds to apolipoprotein D: implications for the protein's function. FEBS Letter 366: 53-56, 1995.
58. Lea OA: Binding properties of progesterone-binding Cyst protein, PBCP. Steroids 52: 337-338, 1988.
59. Milne RW, Rassart E and Marcel YL: Molecular biology of apolipoprotein D. Curr Opin Lipidol 4: 100-106, 1993.
60. Peitsch MC and Boguski MS: Is apolipoprotein D a mammalian bilin-binding protein? The New Biologist 2: 197-206, 1990.
61. Reindl M, Knipping G, Wicher I, Dilitz E, Egg R, Deisenhammer F and Berger T: Increased intrathecal production of apolipoprotein D in multiple sclerosis. J Neuroimmunol 119: 327-332, 2001. (Pubitemid 32918341)
62. Simard J, Veilleux R, Launoit Y de, Haagensen DE and Labrie F: Stimulation of Apolipoprotein D secretion by steroids coincides with inhibition of cell proliferation in human LNCaP prostate cancer cells. Cancer Res 51: 4336-4341, 1991.
63. Sugimoto K, Sigmard J, Haagensen DE and Labrie F: Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells. J Steroid Biochem Mol Biol 51: 167-174, 1994. (Pubitemid 24372860)
64. Lane DM, Boatman KK and McConathy WJ: Serum lipids and apolipoproteins in women with breast masses. Breast Cancer Res Treat 34: 161-169, 1995.
65. Liotta LA: Tumor invasion and metastases: role of the basement membrane. Am J Pathol 117: 339-348, 1984.
66. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM and McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47: 3239-3245, 1987.
67. Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, De Falco V, Celetti A, Giannini R, Basolo F, Melillo RM and Santoro M: Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab 90: 5270-5278, 2005.
68. Hu Z, Lin D, Yuan J, Xiao T, et al: Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 11: 4646-4652, 2005.
69. Zhang DT, Yuan J, Yang L, et al: Osteopontin expression and its relation to invasion and metastases in gastric cancer. Zhonghua ZhongLiu ZaZhi 27: 167-169, 2005.
70. 3 24-Hydroxylase): Implications for differing mechanisms of regulation and involvement of multiple factors. Endocrinology 136: 3971-3982, 2005.
71. 3 regulates the biosynthesis of osteopontin, a bone-derived cell attachment protein, in clonal osteoblast-like osteosarcoma cells. Coll Relat Res 7: 305-313, 1987.
72. Garland C, Shekelle RB, Barrett-Connor E, Criqui MH and Rossof AH: Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet 1: 307-309, 1985. (Pubitemid 15157126)
73. Smith EL, Walworth NC and Holick MF: Effect of 1alpha-25-dihydroxyvitamin D3 on the morphological and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 86: 709-714, 1987.
74. Rocker D, David A, Liberman UA, Garach-Jehoshua O and Koren R: 1,25-dihydroxyvitamin D3 potentiates the cytotoxic effect of TNF on human breast cancer cells. Mol Cell Endocrinol 106: 157-162, 1994.
75. El Abdaimi K, Dion N, Papavasiliou V, Cardinal PE, Binderup L, Goltzman D, SteMarie LG and Kremer R: The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res 60: 4412-4418, 2000.
76. Mantell DJ, Owens PE, Bundred NJ, Mawer EB and Canfield AE: 1alpha, 25-dihydroxyvitamin D3 inhibits angiogenesis in vitro and in vivo. Circ Res 87: 214-220, 2000.
77. Simboli-Campbell M, Narvaez CJ, Tenniswood M and Melsh JE: 1,25-dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 58: 367-376, 1996. (Pubitemid 26348970)
78. Simboli-Campbell M, Narvaez CJ, VanWeelden K, Tenniswood M and Welsh JE: Comparative effects of 1,25-(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 cells. Breast Cancer Res Treat 42: 32-41, 1997.
79. Welsh JE: Induction of apoptosis in breast cancer cells in response to vitamin D and anti-estrogens. Biochem Cell Biol 72: 537-545, 1994.
80. 3-induced G1/S block in HL60 cells to S phase. J Cell Physiol 183: 238-246, 2000.
81. Escaleira MTF and Brentani MM: Vitamin D3 receptor (VDR) expression in HC-11 mammary cells: regulation by growth-modulatory agents, differentiation, and Ha-ras transformation. Breast Cancer Res Treat 54: 123-134, 1999.
82. Phillips K, Park MA, Quarrie LH, Boutinaud M, Lochrie JD, Flint DJ, Allan GJ and Beattie J: Hormonal control of IGF-binding protein (IGFBP)-5 and IGFBP-2 secretion during differentiation of the HC11 mouse mammary epithelial cell line. J Mol Endocrinol 31: 197-208, 2003.